Search Results
Jul 28, 2026, 07:00 ET Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Jul 27, 2026, 06:10 ET Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Jul 27, 2026, 06:10 ET 歌禮宣布每月一次皮下注射GLP-1R/GIPR/GCGR三靶點激動劑多肽ASC37在飲食誘導肥胖小鼠模型中展現出優越的減重效果
R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），和ASC30_48 FDC，ASC30（GLP-1RA）與ASC48（GIP RA）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Jul 24, 2026, 18:37 ET Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
and is projected to reach US$295 billion by 2033. Demand is currently outstripping licensed supply: as of this release, Semaglutide (GLP-1) is on an industry-wide three-week backorder, underscoring the market's need for supply chains that are properly licensed, manufactured
More news about: Vector Sciences & Therapeutics
Jul 24, 2026, 12:46 ET Gundry MD® Daily Weight Advantage™ Named Best Weight Management Supplement of 2026 by NutraIngredients-USA
designed to support the body's own production of key gut-signaling molecules, including cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) — the same "fullness" and blood-sugar hormones your gut releases naturally after a satisfying meal. By helping activate these signals, the formula
More news about: Gundry MD
Jul 24, 2026, 10:02 ET Five Ways to Get the Most from a GLP-1 Medication
navigating weight-management treatment as part of Kroger's new GLP-1 Complete Support ProgramCINCINNATI, July 24, 2026 /PRNewswire/ -- GLP-1 medications are changing what is possible for many patients
More news about: The Kroger Co.
Jul 23, 2026, 09:00 ET As GLP-1 Indications Expand, Novellia Launches Patient Registry to Fill Knowledge Gaps Left by Traditional Datasets
real-world data company that unifies patients' clinical histories across every provider and payer they've used, today announced the launch of its GLP-1 and Metabolic Health Registry, designed to give healthcare organizations unparalleled visibility into how these therapies are actively performing
More news about: Novellia
Jul 23, 2026, 07:05 ET Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity.
More news about: Viking Therapeutics, Inc.
Jul 23, 2026, 06:45 ET Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults
More news about: Eli Lilly and Company
Jul 23, 2026, 06:00 ET West Reports Second-Quarter 2026 Results
business which benefited from continued strength in Biologics, a favorable mix shift from HVP upgrades including Annex 1, and ongoing growth in GLP-1 elastomers. The robust sales growth drove strong operating income margin expansion as compared to prior year. As a result of our team's strong
More news about: West Pharmaceutical Services, Inc.
Jul 23, 2026, 05:26 ET Sentante's CE-marked robotic platform is building the data foundation for endovascular physical AI
the system."Over the past year the company has run a world-first transatlantic remote thrombectomy on perfused human cadaver models and a GLP animal study of 24 remote procedures across three continents, each adding to a dataset built under procedure-authentic conditions.The CE-marked
More news about: Sentante
Jul 22, 2026, 20:10 ET Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Jul 22, 2026, 20:10 ET 歌禮宣佈將在第62屆歐洲糖尿病研究協會（EASD）年會上以口頭討論形式匯報ASC36_35 FDC減重效果優於eloralintide聯合tirzepatide的臨床前數據
R/GIPR雙靶點激動劑多肽，ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，ASC39，一款類似eloralintide、對胰澱素具有選擇性的強效口服小分子胰澱素受體激動劑，ASC30_39 FDC，ASC30（GLP-1RA）與ASC39（胰澱素受體激動劑）的固定劑量復方制劑（FDC），和ASC30_48 FDC，ASC30（GLP-1RA）與ASC48（GIP RA）的固定劑量復方制劑（FDC），用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Jul 22, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735
More news about: Viking Therapeutics, Inc.
Jul 22, 2026, 09:35 ET Get A Drip among first providers of newly approved oral Wegovy in the UK
using GLP-1 for the first time.Dr. Luke Pratsides, NHS GP and Chief Medical Officer at Get A Drip, said: "For many patients, injections remain a significant barrier to treatment. The availability of an oral formulation is a major break-through in the use of GLP-1, as it removes
More news about: Get A Drip
Jul 22, 2026, 09:00 ET MHW Benefit Partners Launches Integrated Solution to Give Employers Greater Clarity and Control Over Healthcare Spend
enterprises, including:Clinical Programs. Proactive support to help employees navigate complex therapies, including GLP-1 and specialty medications, and stay on track.Collaborative Pricing. Bundled administrative fees, percentage of savings solutions,
More news about: MHW Benefit Partners
Jul 22, 2026, 08:45 ET The Protein Paradox: New Survey Finds Consumers Are Calling Time-Out on Protein Gimmicks
Study of 2,000 Americans reveals a nation snacking 4.5 times a day and increasingly adopting GLP-1's are still confused by protein marketing and ingredient listsMINONG, Wis., July 22, 2026
More news about: Link Snacks, Inc.
Jul 21, 2026, 13:49 ET Parker Waichman LLP Comments on Growing Public Attention Surrounding GLP-1 Vision Loss Litigation
these allegations, and no court has determined that GLP-1 medications cause NAION.The lawsuits follow the publication of multiple peer-reviewed scientific studies evaluating a potential association between GLP-1 medications and NAION. As the litigation progresses, the
More news about: Parker Waichman LLP
Jul 21, 2026, 10:20 ET CRISP POWER Debuts First National Campaign as Protein Snacking Hits an Inflection Point
HAUPPAUGE, N.Y., July 21, 2026 /PRNewswire/ -- American consumers are tracking macros, managing GLP-1 protocols, and scrutinizing labels like never before, and they're still reaching for snacks that just taste good.
More news about: CRISP POWER Protein Pretzels
Jul 21, 2026, 09:31 ET WELLGISTICS HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC.
leveraging unique drug-adjunct products to tailor patient-specific solutions through the Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases. The Company intends to leverage Health Lives Here's unique patient-engagement infrastructure to consolidate
More news about: DataMeds AI, Inc.
Jul 21, 2026, 09:00 ET A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Viking Therapeutics sits in the adjacent metabolic-disease arena, developing GLP-1-based therapies for obesity and related conditions. It is not a cell-therapy company, but it belongs in the frame because it illustrates the scale
More news about: American News Group
Jul 21, 2026, 08:44 ET Open Dental Becomes First Electronic Dental Record Technology to Connect to Kno2, Advancing Dental Interoperability Nationwide
providers and track referral follow through.For example, a patient who recently started a GLP-1 medication may not think to mention it during a dental visit. When this information is available through their medical record, the dental provider
More news about: Kno2
Jul 21, 2026, 08:00 ET New Perspective Suggests Emerging Obesity Medications May Unlock Plant-Forward Eating
create an unprecedented opportunity to help patients adopt healthier, more plant-forward dietary patterns. EOMs such as glucagon-like peptide-1 (GLP-1) receptor agonists quiet "food noise"—the persistent, intrusive thoughts about food that have historically made it difficult for many people
More news about: Soy Nutrition Institute Global
Jul 21, 2026, 05:00 ET Abacus Health Solutions Named Preferred Vendor of American Society for Healthcare Human Resources Administration
Trusted by Leading Health Systems for Diabetes and GLP-1 Weight Management SolutionsCRANSTON, R.I., July 21, 2026 /PRNewswire/ -- Abacus Health Solutions, a leader in chronic disease management solutions,
More news about: Abacus Health Solutions
Jul 21, 2026, 05:00 ET Study Points to New Strategy for TB Meningitis Care
to calm harmful immune responses while still allowing the body to fight TB—and identified several approved drugs, including a commonly used GLP-1 called semaglutide, that outperformed corticosteroids in reducing harmful inflammation induced during TB meningitis."These findings are important
More news about: Cincinnati Children's Hospital Medical Center